|
Jan 12
|
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
|
|
Jan 11
|
Here's Why Astrazeneca (AZN) Fell More Than Broader Market
|
|
Jan 10
|
JPM's annual healthcare conference: Here's what's next for GLP-1s and the weight loss market
|
|
Dec 29
|
Biotech Stocks Were Tanking. The Cure? M&A.
|
|
Dec 29
|
Astrazeneca (AZN) Ascends While Market Falls: Some Facts to Note
|
|
Dec 29
|
2023 Will Go Down As The Year Pharma Showed Its Determination To Beat Cancer
|
|
Dec 28
|
Buy AstraZeneca Stock. It Looks Much Better Going Into 2024.
|
|
Dec 27
|
Astrazeneca (AZN) Surpasses Market Returns: Some Facts Worth Knowing
|
|
Dec 27
|
Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned
|
|
Dec 27
|
AstraZeneca (AZN) Set to Acquire Gracell for $1.2 Billion
|
|
Dec 27
|
AstraZeneca PLC (AZN) is Attracting Investor Attention: Here is What You Should Know
|
|
Dec 27
|
Trending tickers: Intel | Tencent | RayzeBio | Astrazeneca
|
|
Dec 27
|
16 Most Promising Dividend Stocks According to Analysts
|
|
Dec 27
|
PRESS DIGEST-British Business - Dec 27
|
|
Dec 26
|
AstraZeneca to Acquire Gracell in $1.2 Billion Deal to Further Cell Therapy Goals
|
|
Dec 26
|
AstraZeneca Bolsters Cell Therapy Pipeline With Over $1B Deal For China-Based Gracell Biotechnologies
|
|
Dec 22
|
Ionis (IONS), AstraZeneca's Eplontersen Receives FDA Nod
|
|
Dec 22
|
Pharma Stock Roundup: FDA Nod to AZN's Eplontersen, CRL to MRK's Cough Candidate
|
|
Dec 22
|
These 3 Big Pharma Stocks Are Making Big Plays With AI
|
|
Dec 22
|
Ionis, Astrazeneca win FDA approval of competitor to Alnylam drug
|